Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

RSNA

  • Home
  •  
  • RSNA



  • Most Read
  • Latest Comments
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

  • 4DMedical’s tech platform now unambiguously in early commercialisation
    4DMedical’s tech platform now unambiguously in early commercialisation
    • News

  • 4DMedical gains momentum as commercialisation gets underway
    4DMedical gains momentum as commercialisation gets underway
    • News

  • 4DMedical to compete with fairy bread for best Aussie invention
    4DMedical to compete with fairy bread for best Aussie invention
    • News

  • Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product
    • News

    Another US win for 4D Medical with FDA approval for CT lung ventilation analysis product

    The US Food and Drug Administration (FDA) has given the green light to respiratory imaging technology company 4DMedical (ASX: 4DX) for its CT-based lung ventilation analysis product (CT LVAS™). This FDA clearance will allow 4DMedical to leverage the US’s available CT hardware and boost its presence in the region. The FDA clearance follows the rollout

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.